This inventor holds 2 USPTO granted patents. Top assignee: Cogent Limited. Active years: 2000-2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000-2003
Title: Martin Patrick Cranage: Innovator in HCMV Glycoprotein Research.
Introduction: Martin Patrick Cranage is a distinguished inventor based in Cambridge, GB. He has made significant contributions to the field of virology, particularly in the development of vaccines against human cytomegalovirus (HCMV). His innovative work has led to the identification and production of critical glycoproteins that play a vital role in vaccine development.
Latest Patents: Cranage holds two notable patents related to HCMV glycoproteins. His latest patents focus on processes for the production of HCMV glycoproteins, antibodies thereto, and HCMV vaccines. The gB and gH proteins have been identified and encoded by specific DNA fragments within the HCMV genome. These proteins have been incorporated into recombinant vaccinia vectors and expressed in host animals, demonstrating their potential to raise HCMV-neutralizing antibodies.
Career Highlights: Throughout his career, Cranage has been dedicated to advancing the understanding of HCMV and its implications for human health. His research has paved the way for innovative approaches to vaccine development, showcasing the potential of glycoproteins in both therapeutic and diagnostic applications.
Collaborations: Cranage has collaborated with esteemed colleagues, including Geoffrey Lilley Smith and Barclay George Barrell. These partnerships have enriched his research and contributed to the successful development of his patented
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile